Overview
TB-500 is a synthetic peptide fragment corresponding to the active region (amino acids 17–23) of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein found in virtually all human and animal cells. Thymosin beta-4 is the principal actin-sequestering protein in eukaryotic cells, playing a fundamental role in cytoskeletal organization, cell migration, and tissue repair processes.
The clinical interest in TB-500 stems from thymosin beta-4's remarkable ability to promote multiple phases of tissue repair simultaneously: reducing inflammation, promoting angiogenesis (new blood vessel formation), stimulating stem cell migration, and preventing apoptosis (programmed cell death) in damaged tissues. These properties have been demonstrated across cardiac, neurological, dermal, ocular, and musculoskeletal tissue types in preclinical models.
TB-500 has gained particular attention in veterinary medicine, where it has been used in equine practice for tendon and ligament injuries. In human research contexts, it remains investigational, with several clinical trials exploring Tβ4 for wound healing and cardiac repair. The peptide is not FDA-approved for any human indication.
This guide reviews the current research landscape for TB-500, examining its molecular mechanisms, pharmacological profile, safety data, and the evidence supporting its various proposed therapeutic applications.
Quick facts
- Mechanism
- Actin-sequestering peptide promoting multi-phase tissue repair
- Primary use
- Tissue Repair & Anti-Inflammation
- Evidence
- moderate
- FDA
- Not approved
- Route
- Subcutaneous or intramuscular injection
- Typical results
- Enhanced wound healing and reduced inflammation in animal models within 1–3 weeks
Chemical information
TB-500 (C₃₈H₆₈N₁₀O₁₄) is a regeneration compound with a molecular weight of 889.01 g/mol. Its structural characteristics underpin its biological activity in tissue repair and regeneration.
How TB-500 works
TB-500 exerts its biological effects primarily through its interaction with actin, the most abundant intracellular protein. By sequestering G-actin monomers, TB-500 prevents excessive polymerization into F-actin filaments, thereby maintaining cellular plasticity and enabling rapid cytoskeletal reorganization necessary for cell migration to injury sites. This actin-regulatory function is central to wound healing, as it allows fibroblasts, endothelial cells, and stem cells to mobilize efficiently.
Beyond actin regulation, TB-500 promotes angiogenesis through upregulation of VEGF and other pro-angiogenic factors. The formation of new blood vessels at injury sites ensures adequate oxygen and nutrient delivery, which is critical for tissue regeneration. Studies have shown that TB-500 can promote coronary vessel development in ischemic heart tissue, opening potential applications for cardiac repair following myocardial infarction.
TB-500 also demonstrates potent anti-inflammatory properties by downregulating pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6, while promoting the expression of anti-inflammatory mediators. This balanced immune modulation helps resolve acute inflammation without suppressing the beneficial aspects of the immune response needed for debris clearance and pathogen defense.
Notably, TB-500 has been shown to promote the migration and differentiation of cardiac progenitor cells, epidermal stem cells, and corneal epithelial cells. This stem cell mobilization effect, combined with its anti-apoptotic properties (protecting cells from programmed death via Akt/protein kinase B pathway activation), makes TB-500 a unique multi-modal regenerative agent.
- Actin sequestration: Binds G-actin monomers to maintain cellular plasticity for rapid migration to injury sites
- Angiogenesis promotion: Upregulates VEGF and stimulates new blood vessel formation in ischemic tissues
- Anti-inflammatory modulation: Reduces IL-1β, TNF-α, and IL-6 while preserving beneficial immune responses
- Stem cell mobilization: Promotes migration and differentiation of tissue-specific progenitor cells
- Anti-apoptotic signaling: Activates Akt/PKB pathway to protect damaged cells from programmed death
- Extracellular matrix remodeling: Promotes appropriate collagen deposition and matrix metalloproteinase regulation
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Half-life | ~4–6 hours (estimated) | Supports periodic dosing protocols |
| Bioavailability (SC) | High (>80% estimated) | Effective subcutaneous absorption |
| Distribution | Systemic, crosses BBB | May exert neuroprotective effects centrally |
| Peak plasma | 1–2 hours post-injection | Rapid absorption from injection site |
| Metabolism | Peptidase degradation | Standard peptide catabolism |
Dosing & administration
TB-500 dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for TB-500 is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Injection site discomfort or mild swelling
- • Temporary lethargy or fatigue
- • Head rush or lightheadedness
- • Mild nausea
- • Temporary skin flushing
- • Mild headache
Serious / potential risks
- • Theoretical concern for tumor promotion via angiogenesis (unconfirmed)
- • Potential for excessive tissue growth with prolonged use
- • Unknown long-term effects in humans
- • Risk of contamination from unregulated sources
- • Possible immune system modulation with chronic administration
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Anticoagulants (Warfarin, DOACs) | TB-500 promotes angiogenesis which may affect hemostasis | Monitor coagulation; use with caution |
| Anti-cancer therapies | Angiogenic properties may theoretically interfere with anti-angiogenic drugs | Avoid concurrent use; consult oncologist |
| Immunosuppressants | TB-500's immune-modulatory effects may alter immunosuppressive efficacy | Discuss with prescribing physician |
| Corticosteroids | Both compounds affect inflammation; potential additive or opposing effects | Monitor inflammatory markers; adjust doses as needed |
| BPC-157 | Commonly stacked; complementary mechanisms of action | Frequently combined in research protocols; no adverse interactions reported |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
TB-500 is a regeneration compound with research interest in wound healing, tissue repair, anti-inflammatory, recovery. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying tissue repair and regeneration
- • Individuals interested in wound healing under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
BPC-157
Complementary regenerative peptide commonly combined with TB-500
GHK-Cu
Copper peptide with collagen-stimulating wound healing properties
IGF-1 LR3
Growth factor promoting tissue repair and muscle recovery
MGF
Mechano growth factor supporting muscle repair post-injury
Frequently asked questions
References
- [1] Crockford D, Turjman N, Allan C, Angel J.. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci (2010). doi: 10.1111/j.1749-6632.2010.05492.x PMID: 20633111
- [2] Goldstein AL, Hannappel E, Sosne G, Kleinman HK.. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther (2012). doi: 10.1517/14712598.2012.687045 PMID: 22612436
- [3] Sosne G, Qiu P, Goldstein AL, Wheater M.. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J (2010). doi: 10.1096/fj.09-142307 PMID: 20065103
- [4] Smart N, Risebro CA, Melville AA, et al.. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature (2007). doi: 10.1038/nature05383 PMID: 17167472
- [5] Philp D, Kleinman HK.. Animal studies with thymosin beta4, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci (2010). doi: 10.1111/j.1749-6632.2010.05479.x PMID: 20633099